pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,229 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1557Hematology1354Pulmonology1264Vaccines
  • Cure for HIV must protect long-term survivors from loss of benefits
    The authors, a postdoctoral researcher, a long‑term HIV survivor, and the head of a survivor alliance, argue that a future HIV cure should not jeopardize the support systems that have kept many pat…
    STAT · 23d agoNeutral↗ source
  • Roche's Genentech to invest $750 million to double Oregon manufacturing site
    Roche's Genentech announced a $750 million investment to expand its existing production facility in Oregon, with the goal of doubling its capacity. The expanded site is expected to boost manufactu…
    STAT · 23d agoDealNeutral↗ source
← prev
page 17 of 90
next →
73
fda recalls71
fda medwatch62
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain501
Endocrinology & Metabolism495
Infectious Disease457
  • Takeda wins FDA nod for orexin drug oveporexton, first treatment for narcolepsy type 1 and potential broader uses
    Takeda received FDA approval for oveporexton (brand Orzeyful), an orexin receptor agonist, marking the first approved therapy that targets the orexin system for narcolepsy type 1. The drug mimics…
    Fierce Biotech · 23d agoApprovalPositive↗ source
  • HHS seeks public input on new vaccine recommendation categories under Trump and Kennedy
    A request for information was posted by the Department of Health and Human Services, giving the public a 30‑day window to comment on potential changes to the U.S. vaccine recommendation framework.…
    STAT · 23d agoRegulatoryNeutral↗ source
  • Study suggests cancer patients may be receiving higher doses and longer treatment courses than needed
    Recent analysis highlighted that many cancer patients are being treated with larger drug doses and extended therapy durations than may be medically necessary. The pattern raises concerns about unn…
    STAT · 23d agoNegative↗ source
  • Merck’s Ebola vaccine rolled out in the Democratic Republic of Congo
    Scientists have begun administering Merck’s Ebola vaccine in the Democratic Republic of Congo as part of ongoing outbreak response efforts. The vaccine, previously used in emergency settings, is b…
    STAT · 23d agoPositive↗ source
  • Ambros Therapeutics merges with Werewolf, raises $150M to fund phase 3 trial of rare disease drug
    Ambros Therapeutics announced an all‑stock reverse merger with Werewolf Therapeutics, accompanied by a $150 million private placement. The transaction will see the combined company operate under th…
    Fierce Biotech · 23d agoDealPositive↗ source
  • New study shows focal therapy matches surgery and radiation survival while reducing side effects in localized prostate cancer
    Physicians remain split over focal therapy for localized prostate cancer, a technique that targets MRI‑visible lesions with heat, cold, or other energy sources instead of removing the entire gland.…
    STAT · 23d agoPositive readoutNeutral↗ source
  • Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decision
    Activist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M…
    BioPharma Dive · 23d agoNegative↗ source
  • Fromm Family Foods recalls over 5,800 cases of wet dog food in US and Canada over possible metal contamination
    Fromm Family Foods LLC announced on August 21, 2026 that it is voluntarily recalling 3,852 cases of its Turkey Pâté Wet dog food and 1,973 cases of its Diner Classics Milo's Meatloaf Pâté Wet dog f…
    fda recalls · 22d agoRegulatoryNegative↗ source
  • Spruce Biosciences appoints former Zevra Therapeutics CMO Adrian Quartel
    Spruce Biosciences announced the hiring of Adrian Quartel as its new chief medical officer. Quartel joins Spruce after serving as CMO at Zevra Therapeutics, where he oversaw clinical development.…
    STAT · 23d agoNeutral↗ source
  • Lil Nas X’s bipolar diagnosis highlights the fear many high achievers have of mental-health treatment
    Lil Nas X recently revealed that he has been diagnosed with bipolar disorder. The article notes that he had suspected something was wrong for years but delayed seeking help because he was worried a…
    STAT · 23d agoNeutral↗ source
  • Moderna’s melanoma vaccine trial success sparks $45 billion market value surge
    Moderna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…
    BioPharma Dive · 24d agoPositive readoutPositive↗ source
  • Regeneron’s ultra-rare bone disorder drug receives U.S. approval after 30-year development
    Regeneron Pharmaceuticals announced that its therapy for an ultra-rare condition in which bone forms in soft tissue has been approved by the U.S. Food and Drug Administration. The disease, sometim…
    STAT · 24d agoApprovalPositive↗ source
  • Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough year
    Merck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an imm…
    STAT · 24d agoPositive readoutPositive↗ source
  • Moderna's cancer vaccine boost lifts stock, sparks talk of Keytruda-like reach
    Moderna’s shares surged 177% after a phase 3 topline win for its Merck‑partnered cancer vaccine, intismeran autogene, was disclosed. The data, released on Wednesday, added roughly $45 billion to Mo…
    Fierce Biotech · 24d agoPositive readoutPositive↗ source
  • FDA approves Ultragenyx gene therapy and Regeneron ultra-rare disease drug
    The Food and Drug Administration gave the green light to a gene‑therapy product from Ultragenyx, marking a new treatment option in the company’s pipeline. In a separate decision, Regeneron secured…
    STAT · 24d agoApprovalPositive↗ source
  • FDA clears Vitestro's Aletta, first robotic blood draw device for U.S. clinics
    The U.S. Food and Drug Administration has granted clearance to Vitestro's Aletta, making it the first standalone robotic system approved to draw blood without direct human handling. Aletta can per…
    Fierce Biotech · 24d agoApprovalPositive↗ source
  • Trump nominates Heidi Overton as FDA Commissioner as agency releases CGT Q&A guidance
    The U.S. Food and Drug Administration issued final guidance that answers common questions about developing cellular and gene therapy products. The document aims to clarify regulatory expectations f…
    raps · 24d agoRegulatoryNeutral↗ source
  • Ultragenyx secures FDA approval for Glenglycos, first gene therapy for GSD Ia
    Ultragenyx announced FDA approval of Glenglycos, a one-time gene therapy for glycogen storage disease type Ia, a rare genetic disorder. The therapy delivers a functional gene to the liver to resto…
    BioPharma Dive · 24d agoApprovalPositive↗ source
  • Capricor Therapeutics likely faces FDA rejection of its Duchenne cell therapy
    Capricor Therapeutics is working to avoid an imminent FDA rejection of its cell‑based treatment for Duchenne muscular dystrophy. The company says it remains confident in the drug, but the regulator…
    STAT · 24d agoRegulatoryNegative↗ source
  • Medigen partners with Charles River to advance multivalent enterovirus vaccine globally
    Charles River Laboratories and Taiwan's Medigen Vaccine Biologics announced a collaboration to prepare Medigen’s multivalent enterovirus vaccine for worldwide use. The partnership will focus on ch…
    Fierce Biotech · 24d agoDealPositive↗ source
  • Chai Discovery partners with Bristol Myers Squibb to use AI for antibody discovery
    Chai Discovery, an AI-driven drug discovery company, announced a collaboration with Bristol Myers Squibb to apply its artificial-intelligence models to therapeutic antibody research. The partnershi…
    Fierce Biotech · 24d agoDealPositive↗ source
  • Eli Lilly partners with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases
    Eli Lilly announced a collaboration with Boston-based Amplitude Therapeutics, a company that emerged from Lilly’s Gateway Labs incubator. The partnership will focus on developing trans-amplifying…
    Fierce Biotech · 24d agoDealPositive↗ source
  • Capricor’s Duchenne drug deramiocel receives negative FDA advisory vote on heart outcome
    Mindy Leffler, a parent of a young man with Duchenne muscular dystrophy, writes an opinion piece about Capricor’s phase 3 study of its drug deramiocel. She describes her son’s experience living ind…
    STAT · 24d agoRegulatoryNegative↗ source